Meta ads aren’t a realistic plan for a research peptide store, and Google Ads for peptides is open only to a narrow slice: genuine B2B lab suppliers, SKU by SKU, for products Google’s policy doesn’t catch. For most catalogs, plan your growth without paid product ads. Google’s policy bars promotion of certain substances “regardless of any claims of legality,” Meta’s policy is broad, and accounts that try anyway tend to end up suspended, often along with accounts linked to them.
That’s not the answer most founders want, and it isn’t quite the same answer for a certified clinic or telehealth brand. Below is what Google’s and Meta’s policies say about peptides at the time of writing (late 2026), why accounts get banned, what we refuse to do for anyone, and where peptide brands actually find customers instead.
Google Ads for peptides: what the policy says
Google’s healthcare and medicines policy has a section on unapproved substances. The policy page opens with: “Google doesn’t allow the promotion of certain products, regardless of any claims of legality.” It covers everything on a non-exhaustive list of unapproved pharmaceuticals and supplements, plus:
- “Products that have been subject to any government or regulatory action or warning”
- “Products with names that are confusingly similar to an unapproved pharmaceutical or supplement”
The example list itself (around 135 entries, mostly branded slimming and prohormone products) doesn’t name BPC-157, TB-500, SARMs or any peptide. Some founders read that as permission. Google says the list is examples only, and the clauses above do the work. Our reading, and this is inference rather than Google’s wording: compounds named in FDA warning letters are likely caught by the “government or regulatory action or warning” clause. With the FDA sending letters to peptide sellers in 2025 and again through 2026, that covers a lot of a typical catalog.
There’s a practical signal too. When we ran peptide terms through Google’s Keyword Planner in October 2026, it refused to suggest related ideas for any peptide seed and showed no bid range for most peptide terms. Google treats the whole topic as restricted.
Google Ads for peptide clinics
Licensed clinics and telehealth practices sit in a different place from research suppliers, but the unapproved substances rule still applies to them. Google says it doesn’t allow the promotion of certain products “regardless of any claims of legality”, and that includes products that have been “subject to any government or regulatory action or warning” (Google’s unapproved substances policy). A prescription doesn’t change that.
What a clinic can usually advertise is the practice itself: consultations, providers, location and the services it offers under its license, with no outcome promises. Ads for prescription medicines, online pharmacies and some telehealth services need Google’s healthcare certification first, and in the US that certification relies on LegitScript for the businesses it covers. That’s why we pair clinic ads with LegitScript application prep and run them through our healthcare PPC service.
Google Shopping and Merchant Center
Shopping ads don’t offer a side door. Merchant Center’s policy applies the same unapproved substances rules to product listings and extends the ban to “substances with similar chemical composition.” It also states that “Offering prescription drugs without a prescription is not allowed.”
So renaming products, or listing them under a generic category, doesn’t help. The chemical-composition wording catches exactly that. What Shopping does allow is a real B2B supplier listing compounds the policy doesn’t cover, which is narrower than most catalogs. We check every SKU against the policy before it goes into a feed, and that check is where our healthcare PPC work for research suppliers starts.
What Meta’s ad policy says about peptides
Meta’s Unsafe Supplements policy says: “Unsafe supplements include but are not limited to: anabolic steroids, chitosan,” along with comfrey, DHEA, ephedra and human growth hormones. It doesn’t name peptides or SARMs.
“Not named” isn’t the same as “allowed.” The phrase “include but are not limited to” leaves reviewers wide discretion. Meta also has a separate drugs and pharmaceuticals policy; we couldn’t verify its current wording, so we won’t quote it here. For online pharmacies and telehealth advertisers, a 2026 industry guide reports that Meta requires advertisers to be “actively LegitScript certified.”
Monitoring is getting sharper, not looser. LegitScript reported in December 2025 that problematic peptide ads were up 308% in 2024 compared with 2023, and it named “Research Use Only” language as a tactic used to “blur the line.” An RUO label in your ad or on your landing page isn’t a shield. It’s one of the things reviewers are trained to look for.
Why peptide ad accounts get suspended
The suspensions we hear about follow a pattern:
- The landing page is reviewed, not just the ad. A clean ad pointing at a store full of restricted compounds is still promoting those compounds.
- Product names trigger the policy. Names that match, or are confusingly similar to, restricted substances get flagged in ads, feeds and landing pages.
- Workarounds get treated as worse than the original violation. Google treats attempts to get around its review as circumventing systems, which typically means suspension without warning, and related accounts sharing payment details, domains or users can go down with it.
- Ad copy is evidence. Under 21 CFR 201.128, the FDA can establish intended use from “advertising matter.” Ads that hint at results are a record of how you market, sitting in someone else’s system.
Is there any version that’s allowed?
For certified healthcare businesses, possibly. Clinics, pharmacies and telehealth brands with LegitScript Healthcare Certification have a route on platforms that require it, within each platform’s healthcare policy. Even then, specific compounds may be off limits: LegitScript wrote in September 2026 that BPC-157, TB-500, retatrutide and cagrilintide are “not currently eligible for compounding, sale, or use,” and certification follows current law, not expected rules.
For research-use-only stores, we don’t know of a policy line that makes product advertising safe for anything the unapproved substances clause catches. Genuine B2B lab suppliers can sometimes list the SKUs it doesn’t catch, checked one at a time. What about bidding only on your own brand name? No policy we’ve seen carves that out. The landing page still gets reviewed, and a brand campaign pointing at a peptide catalog is still promoting the catalog. We wouldn’t run it.
What we refuse to do, and why it backfires
We get asked for these regularly. We don’t do them, for clients or for ourselves:
- Cloaking: showing reviewers one page and visitors another.
- Bridge or “white” pages: a clean site that runs the ads and funnels clicks to the real store.
- Coded product names chosen to slip past filters. The “confusingly similar” and “similar chemical composition” clauses exist for exactly this.
- New accounts after a suspension, or renting “aged” or agency-owned ad accounts.
- Ads for a “research blog” whose job is to send traffic to the store.
Beyond the ethics, they backfire on their own terms. Suspensions spread to linked accounts. Ad spend is lost mid-campaign. LegitScript tracks peptide advertising and publishes guidance for payment processors, so an ad-policy problem and a payments problem tend to travel together. And every one of these tactics is documented evidence of intent. We work with research suppliers who want to run a clean, defensible business, and we don’t help anyone dress up human-use sales as research.
What works instead for peptide brands
Growth for a peptide brand comes from channels you own or control. In rough order of what we’d prioritize:
Search engine optimization. Brand searches are the bulk of organic traffic across the peptide stores we manage, and buyers search for COAs and testing. Our post on peptide SEO without medical claims sets out the plan, and it’s the core of our peptide SEO service.
Email to your own list. Read the platform’s acceptable use policy first. Omnisend prohibits “drugs for research purposes,” Klaviyo prohibits pharmaceutical products, and we haven’t found an email platform that publicly says it accepts research peptides. Ask in writing and keep your list exported.
Direct research buyers. If you’re genuinely RUO, your customers are labs and institutions. They buy through quotes, procurement and relationships, which reward a clear catalog, fast COA access and someone who answers the phone.
Partners, carefully. Affiliates and resellers can work, but you’re answerable for what they say. Put written rules in place (no dosing, no effects, no before/after), audit their pages, and drop anyone who breaks them. Because affiliate statements can count as evidence of intended use, have a lawyer who knows FDA and FTC rules review the program terms.
Communities, as a supplier. Answer questions about testing, shipping and quality where research buyers gather. Don’t astroturf, and don’t discuss effects.
What we’d do this week
If you have a live ad account promoting peptide products the policy catches, pause it before a reviewer does it for you, and move that budget into COA pages and brand protection. If you were suspended, don’t open a replacement account. Read the suspension notice, fix the site, and decide whether an appeal is even worth it given your catalog.
If you’d like a growth plan that doesn’t depend on ad accounts staying alive, that’s the work we do at Peptide Marketing HQ.
FAQ
Can I run Google Ads for a research peptide store?
For most catalogs, no. Google bars promotion of certain substances “regardless of any claims of legality,” including products subject to regulatory action or warnings and products with confusingly similar names. A genuine B2B lab supplier can sometimes list the SKUs the policy doesn’t catch; we check each one.
Are peptides banned on Meta ads?
Meta’s Unsafe Supplements policy doesn’t name peptides, but its list is “not limited to” the examples given, and reviewers have wide discretion. Telehealth and pharmacy advertisers are reported to need active LegitScript certification. A research peptide store should not expect product ads to run.
Can I advertise just my brand name instead of products?
We haven’t seen any policy that carves out brand-only campaigns for restricted products. The landing page is reviewed along with the ad, so a brand campaign leading to a peptide catalog is still promoting the catalog.
What should I do if my ad account was suspended for peptides?
Don’t open a new account, buy one or use someone else’s, because that can be treated as circumventing systems and take linked accounts down too. Fix the site, read the notice carefully, and shift budget into SEO and email.

